Physician profile
Daniel Albershardt
NPI 1295056455
$11,284.14
in general payments reported to CMS, 2019-2025
9 companies · $2,677 in 2025
The $2,677 reported for 2025 was more than what 97% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $863 · 2022: $1,269 · 2023: $332 · 2024: $6,144 · 2025: $2,677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,000 · Travel and Lodging: $2,290 · Food and Beverage: $1,863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,000.00 |
| Travel and Lodging | $2,289.51 |
| Food and Beverage | $1,862.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fujifilm Sonosite, INC. | $5,173.14 | 2024 | |
| Ge Healthcare | $2,271.05 | 2023-2025 | |
| Pacira Pharmaceuticals Incorporated | $2,131.76 | 2021-2022 | |
| Musculoskeletal Transplant Foundation INC. | $1,410.12 | 2023-2025 | |
| Becton, Dickinson and Company | $130.40 | 2025 | Galaflex |
| Motiva USA, LLC | $98.05 | 2024-2025 | |
| Integra Lifesciences Corporation | $30.44 | 2025 | Integra, Omnigraft, Integra Dermal Regeneration Template |
| Smith+Nephew, INC. | $19.88 | 2024 | Stravix |
| Abbvie INC. | $19.30 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Albershardt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.